Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.91)
# 223
Out of 4,630 analysts
88
Total ratings
67.5%
Success rate
61.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Maintained: Buy | $12 | $4.94 | +142.91% | 3 | Aug 7, 2026 | |
| JANX Janux Therapeutics | Maintained: Buy | $26 | $15.85 | +64.04% | 8 | Aug 7, 2026 | |
| CGON CG Oncology | Reiterated: Buy | $82 → $85 | $75.10 | +13.18% | 9 | Aug 7, 2026 | |
| BDTX Black Diamond Therapeutics | Maintained: Buy | $8 | $1.95 | +310.26% | 5 | Aug 6, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $172 → $210 | $205.15 | +2.36% | 9 | Aug 6, 2026 | |
| OBX Obsidian Therapeutics | Initiated Coverage: Buy | $42 | $27.50 | +52.73% | 1 | Aug 4, 2026 | |
| ORIC ORIC Pharmaceuticals | Rated: Buy | $22 | $13.50 | +62.96% | 7 | Aug 4, 2026 | |
| SMMT Summit Therapeutics | Maintained: Hold | $16 | $13.96 | +14.61% | 5 | Jul 24, 2026 | |
| LONA LeonaBio | Initiated Coverage: Buy | $20 | $7.70 | +159.74% | 1 | May 27, 2026 | |
| TARA Protara Therapeutics | Maintained: Buy | $24 | $4.12 | +482.52% | 7 | May 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $14 → $24 | $27.07 | -11.34% | 4 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $18.41 | -2.23% | 5 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $46.96 | -14.82% | 8 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $12.05 | +231.95% | 3 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $1.80 | - | 1 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 | $28.06 | +28.30% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $2.00 | n/a | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.66 | n/a | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $6.34 | n/a | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.04 | n/a | 1 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $20.75 | n/a | 1 | Oct 31, 2022 |
Relmada Therapeutics
Aug 7, 2026
Maintained: Buy
Price Target: $12
Current: $4.94
Upside: +142.91%
Janux Therapeutics
Aug 7, 2026
Maintained: Buy
Price Target: $26
Current: $15.85
Upside: +64.04%
CG Oncology
Aug 7, 2026
Reiterated: Buy
Price Target: $82 → $85
Current: $75.10
Upside: +13.18%
Black Diamond Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $8
Current: $1.95
Upside: +310.26%
Revolution Medicines
Aug 6, 2026
Maintained: Buy
Price Target: $172 → $210
Current: $205.15
Upside: +2.36%
Obsidian Therapeutics
Aug 4, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $27.50
Upside: +52.73%
ORIC Pharmaceuticals
Aug 4, 2026
Rated: Buy
Price Target: $22
Current: $13.50
Upside: +62.96%
Summit Therapeutics
Jul 24, 2026
Maintained: Hold
Price Target: $16
Current: $13.96
Upside: +14.61%
LeonaBio
May 27, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $7.70
Upside: +159.74%
Protara Therapeutics
May 20, 2026
Maintained: Buy
Price Target: $24
Current: $4.12
Upside: +482.52%
May 15, 2026
Downgraded: Hold
Price Target: $14 → $24
Current: $27.07
Upside: -11.34%
May 12, 2026
Maintained: Buy
Price Target: $18
Current: $18.41
Upside: -2.23%
Apr 20, 2026
Maintained: Buy
Price Target: $40
Current: $46.96
Upside: -14.82%
Apr 20, 2026
Maintained: Buy
Price Target: $40
Current: $12.05
Upside: +231.95%
Mar 26, 2026
Maintained: Buy
Price Target: n/a
Current: $1.80
Upside: -
Dec 8, 2025
Maintained: Buy
Price Target: $36
Current: $28.06
Upside: +28.30%
May 15, 2025
Reiterated: Buy
Price Target: $5
Current: $2.00
Upside: n/a
May 7, 2025
Reiterated: Buy
Price Target: $8
Current: $2.66
Upside: n/a
Apr 1, 2025
Maintained: Hold
Price Target: n/a
Current: $6.34
Upside: n/a
Jul 30, 2024
Downgraded: Hold
Price Target: n/a
Current: $4.04
Upside: n/a
Oct 31, 2022
Initiated Coverage: Hold
Price Target: n/a
Current: $20.75
Upside: n/a